Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.
Elizabeth H PhillipsCatherine BurtonAmy A KirkwoodSharon BarransAnthony LawrieSimon RuleRussell PatmoreRuth PettengellKirit M ArdeshnaSilvia MontotoShankara PaneeshaLaura Clifton-HadleyDavid C LinchAndrew K McMillanPublished in: EJHaem (2020)
This prospective trial demonstrates excellent survival rates with R-CODOX-M/R-IVAC in a high-risk BL cohort. It provides reassuring evidence regarding the feasibility of this regimen and also provides a benchmark for future studies.
Keyphrases
- end stage renal disease
- diffuse large b cell lymphoma
- newly diagnosed
- study protocol
- phase iii
- clinical trial
- chronic kidney disease
- ejection fraction
- phase ii
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- current status
- type diabetes
- cross sectional
- adipose tissue
- patient reported outcomes
- hodgkin lymphoma
- weight loss
- chronic lymphocytic leukemia
- double blind